HK1255056A1 - 抗cd115抗體 - Google Patents

抗cd115抗體

Info

Publication number
HK1255056A1
HK1255056A1 HK18114180.1A HK18114180A HK1255056A1 HK 1255056 A1 HK1255056 A1 HK 1255056A1 HK 18114180 A HK18114180 A HK 18114180A HK 1255056 A1 HK1255056 A1 HK 1255056A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
Prior art date
Application number
HK18114180.1A
Other languages
English (en)
Inventor
John Lippincott
Dana Duey
Original Assignee
Ablexis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablexis Llc filed Critical Ablexis Llc
Publication of HK1255056A1 publication Critical patent/HK1255056A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK18114180.1A 2015-09-16 2018-11-07 抗cd115抗體 HK1255056A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219578P 2015-09-16 2015-09-16
US201562220147P 2015-09-17 2015-09-17
PCT/US2016/052063 WO2017049038A2 (en) 2015-09-16 2016-09-16 Anti-cd115 antibodies

Publications (1)

Publication Number Publication Date
HK1255056A1 true HK1255056A1 (zh) 2019-08-02

Family

ID=58289914

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114180.1A HK1255056A1 (zh) 2015-09-16 2018-11-07 抗cd115抗體

Country Status (8)

Country Link
US (2) US10759861B2 (zh)
EP (1) EP3349794A4 (zh)
KR (1) KR20180054701A (zh)
AU (2) AU2016323582B2 (zh)
CA (1) CA2998350A1 (zh)
HK (1) HK1255056A1 (zh)
MA (1) MA42843A (zh)
WO (1) WO2017049038A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3349794A4 (en) 2015-09-16 2019-07-31 Ablexis, LLC ANTI-CD115 ANTIBODIES
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
WO2018222741A1 (en) * 2017-05-31 2018-12-06 Oklahoma Medical Research Foundation Bispecific antibodies for the treatment of streptococcus pneumonia
US11655297B2 (en) 2017-11-30 2023-05-23 Bayer Aktiengesellschaft ILDR2 antagonists and combinations thereof
EP3894014A4 (en) * 2018-12-13 2022-04-20 Development Center for Biotechnology ANTI-HUMAN CSF-1R ANTIBODIES AND USES THEREOF
WO2021099944A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
US20230078330A1 (en) * 2020-01-27 2023-03-16 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
WO2022235960A1 (en) * 2021-05-06 2022-11-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind variant sars-cov-2 spike proteins
TW202328176A (zh) * 2021-09-07 2023-07-16 美商馬布羅克公司 抗-sars-cov-2抗體組成物及其用途
WO2023064435A2 (en) * 2021-10-15 2023-04-20 The Children's Medical Center Corporation Compositions and methods relating to sars-cov-2 neutralizing antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
DK1704166T3 (en) * 2004-01-07 2015-06-01 Novartis Vaccines & Diagnostic M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CL2008002444A1 (es) 2007-08-21 2009-09-04 Amgen Inc Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
ES2722300T3 (es) * 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US8206715B2 (en) * 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US9873733B2 (en) * 2012-12-20 2018-01-23 Morphosys Ag. Anti-staphylococcal antibodies
EP3349794A4 (en) 2015-09-16 2019-07-31 Ablexis, LLC ANTI-CD115 ANTIBODIES

Also Published As

Publication number Publication date
AU2016323582A1 (en) 2018-04-19
WO2017049038A3 (en) 2017-04-27
US20200308291A1 (en) 2020-10-01
KR20180054701A (ko) 2018-05-24
EP3349794A4 (en) 2019-07-31
US11753478B2 (en) 2023-09-12
MA42843A (fr) 2018-07-25
WO2017049038A2 (en) 2017-03-23
AU2016323582B2 (en) 2022-09-15
AU2022283715A1 (en) 2023-02-02
US20180258175A1 (en) 2018-09-13
EP3349794A2 (en) 2018-07-25
US10759861B2 (en) 2020-09-01
CA2998350A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
HK1253507A1 (zh) 抗 ror1 抗體
HK1254836A1 (zh) 抗-ror1抗體
HK1256116A1 (zh) 抗lag-3抗體
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
HK1246804A1 (zh) Tau結合抗體
ZA201705663B (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
ZA201705662B (en) Anti-transthyretin antibodies
IL255323A0 (en) Anti-fcrn antibodies
HK1255056A1 (zh) 抗cd115抗體
SG11201706126WA (en) Anti-transthyretin antibodies
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022B1 (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201502591D0 (en) Antibodies